儿童肥胖治疗的新方向——前进的道路还是一厢情愿？

IF 4.6 3区医学 Q2 PHARMACOLOGY & PHARMACY

Journal of clinical lipidology Pub Date : 2025-09-01 DOI:10.1016/j.jacl.2025.05.010

Jessica L. Reilly MD , Shruthi Arora MD , Kelsey Chatman MD , Zenobia Cooper MBBS , Daniel S. Hsia MD

{"title":"儿童肥胖治疗的新方向——前进的道路还是一厢情愿？","authors":"Jessica L. Reilly MD , Shruthi Arora MD , Kelsey Chatman MD , Zenobia Cooper MBBS , Daniel S. Hsia MD","doi":"10.1016/j.jacl.2025.05.010","DOIUrl":null,"url":null,"abstract":"<div><h3>BACKGROUND</h3><div>The advent of highly effective pharmacotherapy that induces significant weight loss has revolutionized the treatment of obesity. Since 2020, these medications have been approved for use in children with obesity 12 years of age and older, and the American Academy of Pediatrics 2023 Clinical Practice Guidelines have endorsed their use.</div></div><div><h3>SOURCES OF MATERIAL</h3><div>Specifically, glucagon-like peptide 1 (GLP-1) agonists and similar related nutrient stimulated hormones induce weight loss of >15% of baseline body weight in clinical trials.</div></div><div><h3>ABSTRACT OF FINDINGS</h3><div>However, these benefits must be balanced with the known side effects and other potential unknown effects especially in growing children and adolescents. Moreover, barriers to access and long-term effects of these medications need to be addressed.</div></div><div><h3>CONCLUSION</h3><div>In this review, we discuss important considerations for the utilization of these newer weight loss agents in the rapidly evolving landscape of weight loss pharmacotherapy in children and adolescents.</div></div>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":"19 4","pages":"Pages 54-60"},"PeriodicalIF":4.6000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"New directions in childhood obesity treatment – A path forward or wishful thinking?\",\"authors\":\"Jessica L. Reilly MD , Shruthi Arora MD , Kelsey Chatman MD , Zenobia Cooper MBBS , Daniel S. Hsia MD\",\"doi\":\"10.1016/j.jacl.2025.05.010\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>BACKGROUND</h3><div>The advent of highly effective pharmacotherapy that induces significant weight loss has revolutionized the treatment of obesity. Since 2020, these medications have been approved for use in children with obesity 12 years of age and older, and the American Academy of Pediatrics 2023 Clinical Practice Guidelines have endorsed their use.</div></div><div><h3>SOURCES OF MATERIAL</h3><div>Specifically, glucagon-like peptide 1 (GLP-1) agonists and similar related nutrient stimulated hormones induce weight loss of >15% of baseline body weight in clinical trials.</div></div><div><h3>ABSTRACT OF FINDINGS</h3><div>However, these benefits must be balanced with the known side effects and other potential unknown effects especially in growing children and adolescents. Moreover, barriers to access and long-term effects of these medications need to be addressed.</div></div><div><h3>CONCLUSION</h3><div>In this review, we discuss important considerations for the utilization of these newer weight loss agents in the rapidly evolving landscape of weight loss pharmacotherapy in children and adolescents.</div></div>\",\"PeriodicalId\":15392,\"journal\":{\"name\":\"Journal of clinical lipidology\",\"volume\":\"19 4\",\"pages\":\"Pages 54-60\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of clinical lipidology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1933287425002910\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical lipidology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1933287425002910","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

背景：高效的药物疗法的出现导致了显著的体重减轻，彻底改变了肥胖的治疗。自2020年以来，这些药物已被批准用于12岁及以上的肥胖儿童，美国儿科学会2023年临床实践指南也批准了它们的使用。具体来说，在临床试验中，胰高血糖素样肽1 （GLP-1）激动剂和类似的相关营养刺激激素可使体重减轻15%的基线体重。然而，这些益处必须与已知的副作用和其他潜在的未知影响相平衡，特别是在成长中的儿童和青少年中。此外，需要解决获取这些药物的障碍和这些药物的长期影响。结论在这篇综述中，我们讨论了在快速发展的儿童和青少年减肥药物治疗中使用这些新型减肥药的重要考虑因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

New directions in childhood obesity treatment – A path forward or wishful thinking?

BACKGROUND

The advent of highly effective pharmacotherapy that induces significant weight loss has revolutionized the treatment of obesity. Since 2020, these medications have been approved for use in children with obesity 12 years of age and older, and the American Academy of Pediatrics 2023 Clinical Practice Guidelines have endorsed their use.

SOURCES OF MATERIAL

Specifically, glucagon-like peptide 1 (GLP-1) agonists and similar related nutrient stimulated hormones induce weight loss of >15% of baseline body weight in clinical trials.

ABSTRACT OF FINDINGS

However, these benefits must be balanced with the known side effects and other potential unknown effects especially in growing children and adolescents. Moreover, barriers to access and long-term effects of these medications need to be addressed.

CONCLUSION

In this review, we discuss important considerations for the utilization of these newer weight loss agents in the rapidly evolving landscape of weight loss pharmacotherapy in children and adolescents.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of clinical lipidology 医学-药学

CiteScore

7.00

自引率

6.80%

发文量

209

审稿时长

49 days

期刊介绍： Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. Sections of Journal of clinical lipidology will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.